Beta-2 Adrenergic Agonist Scar Hyperpigmentation Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for hyperpigmentation in scars are inadequate in addressing the underlying cellular and molecular mechanisms, leading to significant psychological distress, especially in individuals with darker skin types, where hyperpigmentation and keloids occur at higher rates.
Innovation Solution
Administration of a β2 AR agonist, such as salbutamol, to modulate β2-adrenergic receptor conformation and activity, reducing scar hyperpigmentation and improving skin scar color matching by enhancing the similarity of scar pigmentation to surrounding skin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies for hyperpigmentation are used, then treatment is provided, but the underlying cellular and molecular mechanisms are not addressed, leading to inadequate results
Solution Approach 1:
The patent applies parameter changes by targeting specific molecular parameters (β2-adrenergic receptor activity) rather than general symptomatic treatment. By changing the physiological parameter of receptor conformation and activity through agonist administration, the treatment addresses the underlying mechanism of hyperpigmentation while achieving clinical improvement.
Solution Approach 2:
The β2-adrenergic receptor agonist serves as an intermediary substance that mediates between the treatment application and the hyperpigmentation pathology. The agonist binds to and modulates the receptor, which then triggers downstream signaling cascades that ultimately reduce melanin production and improve scar pigmentation.
2Manufacturing precision
If β2 AR agonist is administered to reduce scar hyperpigmentation, then skin scar color matching is improved, but the mechanism of melanogenesis modulation must be understood and controlled
Solution Approach 1:
The treatment employs feedback control by monitoring scar pigmentation outcomes and adjusting β2 AR agonist administration accordingly. The modulation of melanogenesis is controlled through feedback from observed pigmentation changes, allowing optimization of treatment dosage and duration to achieve desired color matching while preventing over- or under-treatment.
3Shape
If β2-adrenergic receptor conformation is modulated to reduce hyperpigmentation, then scar appearance is improved, but psychological distress from inadequate current treatments persists
Solution Approach 1:
The patent applies preliminary action by addressing hyperpigmentation during the wound healing process itself, rather than treating it as a separate secondary condition. By administering the β2 AR agonist during scar formation, the treatment prevents or minimizes hyperpigmentation development, thereby improving scar appearance and reducing psychological distress before the condition becomes entrenched.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Salbutamol effectively reduces scar hyperpigmentation, improving skin scar color matching and potentially treating or preventing melanocytic lesions and melanoma by altering melanogenesis pathways, as demonstrated in porcine models and human applications.
Implementation Method 1
Administration of a β2 AR agonist, such as salbutamol, to modulate β2-adrenergic receptor conformation and activity, reducing scar hyperpigmentation
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method for improving skin scar colour matching, for example reducing scar hyperpigmentation, the method comprising administering a therapeutically effective amount of an agent, which positively modulates β2-adrenergic receptor conformation, or receptor activity, or activation thereof, to a subject in need thereof. The subject typically is in need of improving skin scar colour matching, for example reducing scar hyperpigmentation, because the subject has or is at risk of hyperpigmentation. The subject typically is selected as being at risk of hyperpigmentation on the basis of one or more of the following factors: · the subject has previously developed hyperpigmentation of a scar • the subject tans readily on exposure to sunshine or ultraviolet (UV) radiation, rather than burning • the subject has a non-Caucasian racial origin • the subject's skin colour (for example in an area that is not tanned) is considered to be darker than that typical of a naturally fair-haired Caucasian person. The subject may be selected as being at risk of hyperpigmentation because they are at least predominantly of Chinese, black African, Asian or Southern European racial origin, and/or if their skin type can be assessed under the Fitzpatrick Scale as Type III, IV, V or VI.